A phase II trial of cyclophosphamide, etoposide, and cisplatin with combined chest and brain radiotherapy in limited small-cell lung cancer: a Cancer and Leukemia Group B Study.

摘要: Limited-extent small-cell lung carcinoma (SCLC) remains a therapeutic problem with little improvement in complete response (CR) rates and long-term survival the past 5 years. From June 1984 through January 1985, 56 patients limited-extent SCLC were enrolled Cancer Leukemia Group B (CALGB) phase II study using five cycles of cyclophosphamide (500 mg/m2 intravenously [IV] day 1), etoposide (80 IV days 1 to 3), cisplatin (33 3) administered at 3-week intervals (CEP), radiation therapy (50 Gy chest 30 brain) concomitant 4 5, followed by three doxorubicin 1). Of 49 evaluable for response, overall rate was 88%, 57% CRs. The median 14 months; duration CR 10 months, nine CRs remain disease free follow-up 23 months. Toxicity significant: 56% experienced WBC less than 1,000 microL, 32% platelets 25,000 microL 10% hemoglobin 7 g/dL. There one treatment-related septic death. These results are as good best previous CALGB SCLC, despite reduction treatment from 18 We currently variant this multimodality approach our standard management SCLC.